BRAF and ameloblastoma: In the 2017 edition, the genetic profile of ameloblastoma was updated broadly. BRAF p.V600E is the most common activating mutation, affecting the MAPK pathways, and is an early and critical event in the etiopathogenesis of ameloblastoma (14,15). BRAF inhibitor therapy has been proposed for selective cases in the treatment (13,16).